Researchers say the pill, daraxonrasib, works by blocking a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases.
WASHINGTON — A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types of cancer.
“While not curing the cancer, it is a very large step forward,” said Dr. Zev Wainberg, of the University of California, Los Angeles, who helped lead the study.
The drug is called daraxonrasib and it blocks a mutated protein that fuels tumor
Our editorial team includes several staff writers, each contributing their specialized knowledge to enhance the depth and breadth of our event and story coverage.